medigraphic.com
ISSN 2007-3178 (Impreso)
Asociación Mexicana de Cirugía Bucal y Maxilofacial, Colegio Mexicano de Cirugía Bucal y Maxilofacial, A.C.

2019, Número 1

<< Anterior Siguiente >>

Rev Mex Cir Bucal Maxilofac 2019; 15 (1)


Osteonecrosis de los maxilares relacionada con medicamentos. Reporte de un caso por el uso de alendronato

Crespo RPA, Malanche AG, Escamilla SMR

Idioma: Español
Referencias bibliográficas: 19
Paginas: 13-17
Archivo PDF: 215.63 Kb.


RESUMEN

La osteonecrosis de los maxilares relacionada con medicamentos (OMRM) es una patología que, por lo general, se presenta con dolor, inflamación, movilidad dental, alteraciones sensitivas, eritema y ulceración; en ocasiones puede presentarse asintomática. Para su diagnóstico tiene que cumplir con tres parámetros: tratamiento previo con medicamentos antiangiogénicos o antirresortivos, exposición ósea por más de ocho semanas y ausencia de radioterapia. Se presenta un caso clínico de OMRM en estadio 2, relacionado con el consumo de bifosfonatos orales para el tratamiento de la osteoporosis. Fue abordado mediante medicamentos y una fase quirúrgica mínimamente invasiva.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Marx R. Oral and intravenous bisphosphonate induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. 2nd ed. Chicago: Quintessence Publishing; 2011.

  2. Marx R, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63 (11): 1567-1575.

  3. Rollason V, Laverrière A, MacDonald L, Walsh T, Tramèr M, Vogt N. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database Syst Rev. 2016; 26 (2): 1-35.

  4. Ruggiero S et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2014; 72 (10): 1938-1956.

  5. Ruggiero S, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102 (4): 433-441.

  6. Ficarra G, Beninat F. Bisphosphonate-related osteonecrosis of the jaws: the point of view of the oral pathologist clinical cases in mineral and bone metabolism. Clin Cases Miner Bone Metab. 2007; 4 (1): 53-57.

  7. Thumbigere V et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009; 67 (9): 1904-1913.

  8. Mehrotra B. Therapies for the treatment of malignant osteolytic bone disease oral. Oral Maxillofac Surg Clin North Am. 2015; 27 (4): 561-566.

  9. Capsoni F, Longhi M, Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist’s role. Arthritis Res Ther. 2006; 8 (5): 219.

  10. Lee C, David T, Nishime M. Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol. 2007; 33 (6): 371-382.

  11. Soydan S, Uckan S. Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report. J Oral Maxillofac Surg. 2014; 72 (2): 322-326.

  12. Ruggiero S. Emerging concepts in the management and treatment of osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2013; 25 (1): 11-20.

  13. Ruggiero S. Diagnosis and staging of medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2015; 27 (4): 479-487.

  14. Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Drug-induced osteonecrosis of the jaw: the state of the art reumatismo. Reumatismo. 2017; 69 (1): 9-15.

  15. Williams W, O’Ryan F. Management of medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2015; 27 (4): 517-525.

  16. Solomon D, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate associated osteonecrosis of the jaw: prior work and current challenges. Osteoporosis International. 2013; 24 (1): 237-244.

  17. Huang Y, Chang C, Muo C, Tsai C, Shen Y, Wu C. Impact of bisphosphonate-related osteonecrosis of the jaw on osteoporotic patients after dental extraction: a population-based cohort study. PLoS One. 2015; 10 (4): 16.

  18. McCaul J. Pharmacologic modalities in the treatment of osteoradionecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2014; 26 (2): 247-252.

  19. Ruggiero S, Dodson T, Assael L, Landesberg R, Marx R, Mehrotra B et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65 (3): 369-376.




2020     |     www.medigraphic.com